Tumor-selective combination therapy

Paul J Hergenrother; David A Boothman; Joseph S Bair; Lifen Cao; Jinming Gao; Xiumei Huang; Xiuquan Luo; Xinpeng Ma; Zachary Moore; Elizabeth I Parkinson

Tumor-selective combination therapy

Paul J Hergenrother (Inventor), David A Boothman (Inventor), Joseph S Bair (Inventor), Lifen Cao (Inventor), Jinming Gao (Inventor), Xiumei Huang (Inventor), Xiuquan Luo (Inventor), Xinpeng Ma (Inventor), Zachary Moore (Inventor), Elizabeth I Parkinson (Inventor)

Research output: Patent

Abstract

The therapies described herein can be selectively lethal toward a variety of different cancer cell types and cancer conditions in a subject. The combination therapies described herein can be useful for the management, treatment, control, or adjunct treatment of diseases, where the selective lethality is beneficial in chemotherapeutic therapy, particularly where the disease is accompanied by elevated levels of NQO1.

Original language	English (US)
U.S. patent number	10272099
Filing date	4/8/14
State	Published - Apr 30 2019

Library availability

Discover UIUC Full Text

Cite this

@misc{324f2c31834e42ed8b8ade5fe0e6e2e2,

title = "Tumor-selective combination therapy",

abstract = "The therapies described herein can be selectively lethal toward a variety of different cancer cell types and cancer conditions in a subject. The combination therapies described herein can be useful for the management, treatment, control, or adjunct treatment of diseases, where the selective lethality is beneficial in chemotherapeutic therapy, particularly where the disease is accompanied by elevated levels of NQO1.",

author = "Hergenrother, {Paul J} and Boothman, {David A} and Bair, {Joseph S} and Lifen Cao and Jinming Gao and Xiumei Huang and Xiuquan Luo and Xinpeng Ma and Zachary Moore and Parkinson, {Elizabeth I}",

note = "GOVERNMENT SUPPORT This invention was made with government support under contract number CA102792 awarded by the National Institutes of Health. The government has certain rights in the invention.; 10272099",

year = "2019",

month = apr,

day = "30",

language = "English (US)",

type = "Patent",

}

TY - PAT

T1 - Tumor-selective combination therapy

AU - Hergenrother, Paul J

AU - Boothman, David A

AU - Bair, Joseph S

AU - Cao, Lifen

AU - Gao, Jinming

AU - Huang, Xiumei

AU - Luo, Xiuquan

AU - Ma, Xinpeng

AU - Moore, Zachary

AU - Parkinson, Elizabeth I

N1 - GOVERNMENT SUPPORT This invention was made with government support under contract number CA102792 awarded by the National Institutes of Health. The government has certain rights in the invention.

PY - 2019/4/30

Y1 - 2019/4/30

N2 - The therapies described herein can be selectively lethal toward a variety of different cancer cell types and cancer conditions in a subject. The combination therapies described herein can be useful for the management, treatment, control, or adjunct treatment of diseases, where the selective lethality is beneficial in chemotherapeutic therapy, particularly where the disease is accompanied by elevated levels of NQO1.

AB - The therapies described herein can be selectively lethal toward a variety of different cancer cell types and cancer conditions in a subject. The combination therapies described herein can be useful for the management, treatment, control, or adjunct treatment of diseases, where the selective lethality is beneficial in chemotherapeutic therapy, particularly where the disease is accompanied by elevated levels of NQO1.

M3 - Patent

M1 - 10272099

Y2 - 2014/04/08

ER -

Tumor-selective combination therapy

Abstract

Library availability

Fingerprint

Cite this